Orchid Pharma Announces 33rd AGM on Sep 29, 2026, to Discuss FY26 Results & Director Appointments
Orchid Pharma Limited will hold its 33rd AGM on September 29, 2026, via VC/OAVM. The meeting will consider FY26 financial statements, reappoint Mr. Mridul Dhanuka, and appoint Mr. Arjun Dhanuka as Whole-time Director. Approval for related party transactions up to ₹400 crore with Otsuka Chemicals and ratification of Cost Auditor's remuneration are also on the agenda.
The AGM agenda includes significant items such as the adoption of financial statements post-amalgamation, director appointments, and a substantial related party transaction. These decisions have a material impact on the company's governance and business operations.
The announcement is primarily procedural, detailing the upcoming AGM, its agenda, and related financial statements. While it includes appointments and related party transactions, these are standard corporate activities and do not inherently indicate a positive or negative shift in the company's performance or outlook.
Orchid Pharma Limited has announced its 33rd Annual General Meeting (AGM) for the Financial Year 2025-26, scheduled to be held on Tuesday, September 29, 2026, at 12:00 Noon IST. The meeting will be conducted virtually through Video Conferencing (VC) / Other Audio Visual Means (OAVM).
The AGM agenda includes the consideration and adoption of the Revised Audited Standalone and Consolidated Financial Statements for the Financial Year ended March 31, 2026. These financial statements are presented subsequent to the Scheme of Amalgamation between Dhanuka Laboratories Limited and Orchid Pharma Limited, as sanctioned by the National Company Law Tribunal.
Key business items also include the reappointment of Mr. Mridul Dhanuka as Whole Time Director. Furthermore, the meeting will seek member approval for the appointment of Mr. Arjun Dhanuka as Whole-time Director for a period of five years, from September 3, 2026, to September 2, 2031, along with his remuneration.
Other agenda items include the ratification of the Cost Auditor's remuneration for FY 2026-27, set at ₹3,50,000 excluding applicable taxes. Additionally, the company will seek approval for material related party transactions with M/s. Otsuka Chemicals (India) Private Limited, with an expected transaction value of up to ₹400 crore during FY 2026-27.
The Annual Report for FY 2025-26, which includes the Notice of the AGM, has been dispatched to members and is available on the company's website. The cut-off date for voting eligibility is September 22, 2026, with remote e-voting available from September 26 to September 28, 2026.
What to do with a filing like this
Orchid Pharma Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Orchid Pharma Limited. Read the original for the full detail.